Picture of Biocorrx logo

BICX Biocorrx Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m+13.79%
3m-0.68%
6m-18.86%
1yr-25.63%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w High-71.6%
50d MA-5.39%
200d MA-39.59%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equityn/a
Operating Margin-9246.01%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Biocorrx EPS forecast chart

Profile Summary

BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders. The Company's BioCorRx Recovery Program is a non-addictive, medication-assisted treatment (MAT) program for substance abuse that includes peer recovery support. The UnCraveRx Weight Loss Management Program is a medically assisted weight management program that is combined with a virtual platform application. It is also engaged in the research and development of sustained release naltrexone products for the treatment of addiction and other possible disorders. Its products include BICX101 and BICX104. Its lead candidate, BICX101, is a sustained release, injectable naltrexone for the treatment of opioid abuse and alcoholism. It is also developing an implantable naltrexone treatment, BICX104, a long-acting naltrexone implant that can last several months for the treatment of opioid dependence and alcohol use disorders. Its subsidiary is BioCorRx Pharmaceuticals, Inc.

Directors

Last Annual
December 31st, 2021
Last Interim
June 30th, 2022
Incorporated
January 28th, 2008
Public Since
April 16th, 2007
No. of Shareholders
145
No. of Employees
5
Sector
Healthcare Providers & Services
Industry
Healthcare
Exchange
us flag iconPink Sheets on Nasdaq
Shares in Issue
7,086,372

BICX Share Price Performance

Upcoming Events for BICX

Q3 2022 BioCorRx Inc Earnings Release

Similar to BICX

Picture of 4Cable TV International logo

4Cable TV International

us flag iconPink Sheets on Nasdaq

Picture of Abattis Bioceuticals logo

Abattis Bioceuticals

us flag iconPink Sheets on Nasdaq

Picture of Accelera Innovations logo

Accelera Innovations

us flag iconPink Sheets on Nasdaq

Picture of ACI Global logo

ACI Global

us flag iconPink Sheets on Nasdaq

Picture of Quantum Medical Transport logo

Quantum Medical Transport

us flag iconPink Sheets on Nasdaq

FAQ

Or unlock with your email

Or unlock with your email